• Policy
• Finding ways to utilize the Patent-approval linkage system
• by Lee, Hye-Kyung Mar 10, 2022 05:53am

• Policy
• The fatality rate of Omicron is low
• by Lee, Jeong-Hwan Mar 8, 2022 06:08am

• Policy
• DREC rejects reimb of neurofibromatosis drug ‘Koselugo'
• by Lee, Tak-Sun Mar 8, 2022 06:08am

• Policy
• Brukinsa was approved using phase 2 data on MCL indications
• by Lee, Hye-Kyung Mar 4, 2022 05:57am

• Policy
• Janumet's salt change consigned drug have been approved for
• by Lee, Hye-Kyung Mar 4, 2022 05:57am

• Policy
• Ahn Cheol Soo, promised for Vaccine Sovereignty
• by Lee, Jeong-Hwan Mar 3, 2022 06:00am

• Policy
• To establish a pharmaceutical bio-innovation committee
• by Lee, Jeong-Hwan Mar 3, 2022 06:00am

• Policy
• Negotiations with NHIS on Actemra have been completed
• by Lee, Tak-Sun Mar 2, 2022 05:54am

• Policy
• Keytruda is reimbursed as first-line at ₩2,107,642
• by Kim, Jung-Ju Feb 28, 2022 05:54am

• Policy
• BeiGene's Brukinsa has been approved in Korea
• by Lee, Hye-Kyung Feb 28, 2022 05:54am